What exactly changed in the DRTS analyst rating on Feb 24, 2026?

H.C. Wainwright maintained a **Buy** rating and raised the Alpha Tau price target to **$12** from **$9** on February 24, 2026. The firm cited clinical and commercial progress as reasons for the price target increase.

How should investors interpret a maintained Buy in the DRTS analyst rating?

A maintained Buy means the analyst still prefers Alpha Tau versus peers. It signals continued conviction but not a fresh upgrade. Investors should combine this view with company fundamentals and risk tolerance.

Did DRTS stock move after the analyst update and what is the market cap?

Yes. The stock moved **-1.4% (-$0.11)** on the announcement. Alpha Tau Medical Ltd. had a market cap of **$630,528,360** near the update, per the reporting.

Where can I read the H.C. Wainwright note on the DRTS analyst rating?

The H.C. Wainwright note summarized the rating and price target change. A report summary is available on [TheFly](https://thefly.com/permalinks/entry.php/id4299550/7360286394/DRTS-Alpha-Tau-price-target-raised-by--at-HC-Wainwright-heres-why).

Analyst Ratings

H.C. Wainwright Maintained Buy on Alpha Tau Medical Ltd. (DRTS) Feb 2026

ByHuzaifa Zahoor February 25, 2026February 25, 2026

H.C. Wainwright maintained a Buy rating on Alpha Tau Medical Ltd. (DRTS) on February 24, 2026. This DRTS analyst rating included a price target increase to $12 from $9, a clear sign the firm sees stronger near-term value. The market reacted with a modest pullback of -1.4% (-$0.11) on the update. We cover the rating details, price target, and what this action means for investors assessing DRTS.